Benzinga · Jul 24, 2024
$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing - Benzinga
Chain Bridge I (CBRG) announced the acquisition of Phytanix Bio, a pharmaceutical company specializing in cannabinoid-based medicines, for $58 million. The combined entity will be listed on the Nasdaq under the ticker 'PHYX' and focus on developing novel treatments for conditions with unmet medical needs.

